Medtide Inc. (HKG:3880)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
22.26
-0.02 (-0.09%)
Apr 17, 2026, 4:08 PM HKT
Market Cap3.16B
Revenue (ttm)634.40M +28.9%
Net Income241.89M +267.3%
EPS1.81 +332.1%
Shares Out141.80M
PE Ratio12.30
Forward PE9.71
Dividendn/a
Ex-Dividend Daten/a
Volume105,000
Average Volume103,335
Open22.28
Previous Close22.28
Day's Range21.98 - 22.40
52-Week Range21.04 - 41.72
Betan/a
RSI45.77
Earnings DateMar 30, 2026

About Medtide

Medtide Inc., a contract research, development, and manufacturing company, provides early-stage discovery, preclinical research, clinical development, and commercial-stage production services. It offers peptide new chemical entity discovery synthesis, peptide chemistry, manufacturing, and control development and commercial manufacturing services. The company focuses on developing oral and/or injectable glucagon, such as peptide-1 (GLP-1) molecule products. Its research and development technology platform include OmniPeptSynth, PeptiConjuX, Pept... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2020
Employees 566
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 3880
Full Company Profile

Financial Performance

In 2025, Medtide's revenue was 570.09 million, an increase of 28.91% compared to the previous year's 442.23 million. Earnings were 217.37 million, an increase of 267.35%.

Financial numbers in CNY Financial Statements